Henry Schein (NASDAQ:HSIC) Releases Earnings Results, Misses Estimates By $0.04 EPS

Henry Schein (NASDAQ:HSIC - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04), Zacks reports. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the previous year, the business earned $0.66 EPS. Henry Schein's revenue for the quarter was up 5.8% on a year-over-year basis. Henry Schein updated its FY 2025 guidance to 4.800-4.940 EPS and its FY25 guidance to $4.80-4.94 EPS.

Henry Schein Stock Up 0.1 %

HSIC stock traded up $0.05 during midday trading on Friday, hitting $72.17. 11,190,666 shares of the company's stock were exchanged, compared to its average volume of 1,992,676. The stock has a market capitalization of $9.00 billion, a price-to-earnings ratio of 29.70, a price-to-earnings-growth ratio of 2.13 and a beta of 0.91. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The firm has a 50 day moving average price of $74.35 and a 200-day moving average price of $72.42. Henry Schein has a 12-month low of $63.67 and a 12-month high of $82.49.

Analyst Upgrades and Downgrades

HSIC has been the subject of several recent analyst reports. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and raised their price objective for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Barrington Research reiterated an "outperform" rating and set a $90.00 price target on shares of Henry Schein in a research report on Wednesday. StockNews.com upgraded Henry Schein from a "sell" rating to a "hold" rating in a report on Thursday, November 7th. UBS Group reduced their price objective on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday. Finally, Mizuho started coverage on Henry Schein in a research report on Wednesday, December 4th. They set a "neutral" rating and a $75.00 target price on the stock. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.